Xilio Therapeutics (XLO) Institutional Ownership → We’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How) (From Paradigm Press) (Ad) Free XLO Stock Alerts $1.05 +0.03 (+2.94%) (As of 06/7/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Xilio Therapeutics (NASDAQ:XLO)CurrentInstitutional OwnershipPercentage54.29%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$32.40KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$2.20M Get XLO Insider Trade Alerts Want to know when executives and insiders are buying or selling Xilio Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data XLO Institutional Buying and Selling by Quarter Ad Weiss RatingsNvidia has Apple and Microsoft within striking rangeA small handful of companies are working with Nvidia to help ensure that this pivot is a massive success. We call them Nvidia’s “Silent Partners.”Click here to find out who they are. Xilio Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/6/2024 Atlas Venture Life Science Advisors LLC992,912$1.07M0.1%-64.0%2.690% 4/22/2024 PFG Investments LLC30,000$32K0.0%N/A0.087% 2/15/2024 Octagon Capital Advisors LP1,785,000$982K0.2%-23.0%6.481% 11/14/2022Ergoteles LLC12,941$38K0.0%-26.3%0.047% 8/15/2022 Laurion Capital Management LP142,900$417K0.0%N/A0.520% 7/27/2022 Bailard Inc.36,632$107K0.0%N/A0.133% 5/16/2022 Deerfield Management Company L.P. Series C2,078,692$14.70M0.3%-3.5%7.567% 5/12/2022 Monashee Investment Management LLC163,066$1.15M0.3%-23.9%0.594% 2/15/2022Davidson Kempner Capital Management LP29,000$458K0.0%N/A0.109% 2/14/2022 Deerfield Management Company L.P. Series C2,154,061$33.74M0.7%N/A8.078% 2/14/2022 Ghisallo Capital Management LLC30,000$480K0.0%N/A0.113% 2/14/2022 Soleus Capital Management L.P.477,495$7.64M0.8%N/A1.791% 2/11/2022Granite Point Capital Management L.P.10,000$160K0.0%N/A0.038% 2/9/2022AJU IB Investment Co. Ltd.667,742$10.68M14.9%N/A2.504% 2/8/2022 Northern Trust Corp63,034$1.01M0.0%N/A0.236% 2/7/2022 Monashee Investment Management LLC214,253$3.43M0.8%N/A0.803% 2/7/2022 RiverVest Venture Management LLC1,441,444$23.06M16.5%N/A5.406% 2/2/2022 New York State Common Retirement Fund5,568$89K0.0%N/A0.021% (Data available from 1/1/2016 forward) XLO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of XLO shares? During the previous two years, the following institutional investors and hedge funds held shares of Xilio Therapeutics shares: Atlas Venture Life Science Advisors LLC ($1.07M), Octagon Capital Advisors LP ($982K), Laurion Capital Management LP ($417K), Bailard Inc. ($107K), and Ergoteles LLC ($38K), PFG Investments LLC ($32K).Learn more on XLO's institutional investors. What percentage of Xilio Therapeutics stock is owned by institutional investors? 54.29% of Xilio Therapeutics stock is owned by institutional investors. Learn more on XLO's institutional investor holdings. Which institutional investors have been buying Xilio Therapeutics stock? The following institutional investors have purchased Xilio Therapeutics stock in the last 24 months: Laurion Capital Management LP ($142.90K), Bailard Inc. ($36.63K), and PFG Investments LLC ($30K). How much institutional buying is happening at Xilio Therapeutics? Institutional investors have bought a total of 209,532 shares in the last 24 months. This purchase volume represents approximately $556.63K in transactions. Which Xilio Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Xilio Therapeutics stock in the last 24 months: Atlas Venture Life Science Advisors LLC ($1.77M), Octagon Capital Advisors LP ($533.50K), and Ergoteles LLC ($4.61K). How much institutional selling is happening at Xilio Therapeutics? Institutional investors have sold a total of 2,304,539 shares in the last 24 months. This volume of shares sold represents approximately $2.21M in transactions. Related Companies: IMAB Institutional Ownership HOWL Institutional Ownership PRQR Institutional Ownership BMEA Institutional Ownership RGLS Institutional Ownership SGMT Institutional Ownership SYRS Institutional Ownership ANL Institutional Ownership SCPH Institutional Ownership VERU Institutional Ownership This page (NASDAQ:XLO) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t...Porter & Company | SponsoredWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.